Naltrexone

This classification denotes an opiate antagonist with the molecular formula C20H23NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5S6W795CQM, chemically known as morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5.alpha.)- but generally known as naltrexone, which bears US NIH Compound Identifier 4428. European Medicines Agency schedules Naltrexone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09143MIG. The term NALTREXONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules naltrexone in its Anatomical Therapeutic Chemical (ATC) Classification. NALTREXONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule naltrexone under HS 29391900 and SITC 54141. As of Q4 2014, NALTREXONE remains the US FDA Preferred Term for this commodity. Naltrexone bears US NLM identifiers UMLS ID C0027360 and NCI Concept Code C62055. SMILES: O1C2C34C(O)(C(N(CC3)CC3CC3)CC3C4C1C(O)CC3)CCC2=O.